Targeting autoimmunity: expert talks on cell therapy
Targeting autoimmunity: expert talks on cell therapy
For patients with autoimmune diseases, cellular therapies are moving beyond oncology to offer the potential for profound, sustained remission by resetting the aberrant immune system. These expert talks cover the mechanisms, clinical trials, and future potential of cell therapy in this challenging indication.
Latest clinical developments in CAR T cell therapy of autoimmunity
Since the first success of CD19 CAR T cells in treating systemic lupus erythematosus (SLE) more than four years ago, the field of CAR T cells outside of malignant diseases is vibrant. Ever more autoimmune diseases are being treated with CAR T cells, including rheumatologic, but also hematologic, neurologic, dermatologic and also gastroenterological diseases. This presentation will summarize novel developments including toxicities and toxicity management, expand on indications, discuss possible causes of shorter CAR T cell persistence, question immune reconstitution and functional consequences following CAR T, and will touch on mechanistic insights on how CAR T cells achieve responses, what happens in relapse, and if there are biomarkers that predict failure.
Prof. Fabian Müller, MD @ MACS Cell and Gene Therapy Days 2025
Prof. Fabian Müller, MD
Principal Investigator and Attending Physician in Hematology and Oncology, University Clinic Erlangen, Germany
Prof. Müller obtained his MD in Freiburg, Germany and started his clinical education in Hamburg. With a focus on targeting malignant B cells in his early research career, he did a postdoctoral fellowship with Dr. Ira Pastan, at the NCI on resistance to CD22-targeted therapy in ALL and aggressive lymphoma. After his post-doc he continued the work on B cell targeting in Erlangen, Germany, using first antibody-directed therapies and then CAR T cells with a focus on translational concepts including tumor microenvironment and functional aspects of a patient’s immune system. As head of the CAR T cell unit, he pioneers CAR T cell therapies in novel indications including solid tumors and autoimmune diseases.
The long journey of CAR T cells: from hematology to oncology and autoimmune disorders
Prof. Franco Locatelli, MD, from the IRCCS Ospedale Pediatrico Bambino Gesù in Rome, Italy, discusses the journey and evolution of CAR T cells in therapeutic use, from treating hematological and oncological conditions to their more recent applications in autoimmune disorders.
Prof. Franco Locatelli, MD @ MACS Cell and Gene Therapy Days 2025
Prof. Franco Locatelli, MD
Head of Pediatric Hematology and Oncology and Cell and Gene Therapy at Bambino Gesù Children's Hospital, Rome, Italy
Franco Locatelli is Full Professor of Pediatrics at the Catholic University of the Sacred Heart in Rome and Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy at the Bambino Gesù Children’s Hospital in Rome. Prof. Locatelli was President of the Italian Association for Pediatric Haematology/Oncology (AIEOP) from 2004 to 2006 and he served as Chair of the European EWOG-MDS consortium from 2005 to 2011. Prof. Locatelli leads the largest allogeneic hematopoietic stem cell transplantation program in Italy.
He is an expert in pediatric hematological malignant and non-malignant disorders. Prof. Locatelli currently serves as chairperson of the current diagnostic and treatment protocol for children with newly diagnosed acute myeloid leukemia and is the Italian coordinator of the consortium on relapsed acute lymphoblastic leukemia. In addition, Prof. Locatelli is chairperson of the international protocol of chemotherapy-free treatment of childhood acute promyelocytic leukemia, the coordinator of AIEOP’s Acute Non-Lymphoblastic Leukemia Working Group and is the principal investigator of the forthcoming academic global study on conditioning hematopoietic stem cell transplantation in acute lymphoblastic leukemia in children.
During his career, Prof. Locatelli has provided relevant contributions to the study of childhood leukemia, myelodysplastic syndromes, thalassemia, innate immunity, immune reconstitution after transplantation, tumor immunology, induction of tolerance towards alloantigens and anti-viral cellular immunity. His current main research interests are CAR T cells for both B-cell malignancies, brain neoplasia and solid tumors (neuroblastoma), and gene therapy/genome editing for hemoglobinopathies.
Prof. Locatelli is the author or co-author of 1419 peer-reviewed articles published in international journals (including New England Journal of Medicine, JAMA, Nature, Nature Genetics, Nature Communications, The Lancet, Lancet Haematology, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, Journal of Experimental Medicine, Blood, Cancer Research, Leukemia, etc.). With 69,840 citations, he has an H-index of 125 (Scopus source). Since February 2019, Prof. Locatelli is serving as President of the National Council of Health (Consiglio Superiore di Sanità). In December 2021, Prof. Locatelli was nominated 1st Class/Knight Grand Cross (Cavaliere di Gran Croce) by the President of the Italian Republic. Prof. Locatelli was awarded an Honoris Causa Degree in Medicine Biotechnology, by the University of Modena and Reggio Emilia, in March 2025.
CAR T cells for the treatment of B cell-mediated autoimmune diseases
Despite better treatment modalities some patients with systemic lupus erythematosus (SLE) suffer from severe and treatment-resistant disease. This situation puts patients at high risk for organ failure or even death. Furthermore, many patients with SLE have to take long-term, sometimes even life-long immune suppressive medication to control the disease without being able to enjoy drug-free remission.
Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus. Recently, we reported that deep B cell depletion using a single infusion with autologous CD19 chimeric antigen receptor (CAR) T cells induced drug-free clinical remission in severe SLE patients with refractory disease. In this presentation, we present an update on clinical efficacy and safety of the first SLE patients receiving CD19 CAR T cell therapy.
Prof. Andreas Mackensen, MD @ Miltenyi Biotec Cell and Gene Therapy Days 2023
Prof. Andreas Mackensen, MD
Director Oncologic Center, University Clinic Erlangen, Germany
Prof. Andreas Mackensen, MD, received his approbation as physician and MD degree from the University of Freiburg in 1988. After an internship at the University of Freiburg, he was a postdoctoral fellow from the DFG between 1991 and 1993 at the Institute Gustave Roussy, Villejuif. His research focus was on the characterization of tumor-specific immune responses in regressive melanoma.
Back in Freiburg, he completed his training as a hematologist/oncologist and habilitated in Internal Medicine (1998). From 1999-2007 he was Professor (C3) for Hematology/Oncology at the University of Regensburg and initiated one of the first European phase I clinical trials with adoptively transferred tumor-reactive T cells in advanced malignant melanoma.
In 2007, he became a full professor for hematology/oncology and Director of the Dept. of Internal Medicine 5 – Hematology/Oncology at the University of Erlangen. Currently, he is a principal investigator in different investigator-initiated cell-based immunotherapy studies with CAR T cells for patients with hematologic diseases, solid tumors, and autoimmune diseases. Since 2020, he is the Director of the Bavarian Center for Cancer Research (BZKF).
You have previously chosen International as your location.
What do you want to do?